Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from

Vaia Florou1, Andrew E Rosenberg2, Eric Wieder2

  • 1Department of Medicine, Division of Oncology, Sylvester Comprehensive Cancer Center at University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL, 33136, USA. vaia.florou@hsc.utah.edu.

Following publication of the original article [1], the authors have reported that the following sentence "While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells".

Related Concept Videos